Literature DB >> 11973245

High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease.

E Toker1, H Kazokoğlu, N Acar.   

Abstract

AIM: To evaluate the safety and effectiveness of high dose intravenous steroid therapy (HDIST) in Behçet's disease patients with severe posterior segment uveitis attacks.
METHODS: Five patients with ocular Behçet's disease were treated with HDIST for severe posterior segment attacks. Two patients had vasculitis, one patient had papillitis, and the other two had retinitis; four patients also had accompanying severe vitritis. The visual acuities and improvement in ocular signs after HDIST were evaluated.
RESULTS: During HDIST, patients had no systemic complications caused by treatment. All patients responded to HDIST with evidence of a decrease in intraocular inflammatory activity and improved visual acuities within a mean time of 7 (1-15) days of commencing treatment. During follow up three out of five patients had new posterior segment attacks.
CONCLUSION: HDIST is effective in controlling severe, vision threatening acute posterior segment Behçet's uveitis attacks and in improving visual function in a short period of time

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973245      PMCID: PMC1771121          DOI: 10.1136/bjo.86.5.521

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis.

Authors:  D Wakefield; A Jennings; P J McCluskey
Journal:  Clin Exp Ophthalmol       Date:  2000-04       Impact factor: 4.207

2.  Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease.

Authors:  Y Sasamoto; S Ohno; H Matsuda
Journal:  Ophthalmologica       Date:  1990       Impact factor: 3.250

3.  Treatment and visual prognosis in Behçet's disease.

Authors:  D Benezra; E Cohen
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

4.  The rate of visual loss in Behçet's disease.

Authors:  J G Mamo
Journal:  Arch Ophthalmol       Date:  1970-10

5.  Fatal arrhythmia after pulse methylprednisolone therapy.

Authors:  R E Moses; A McCormick; W Nickey
Journal:  Ann Intern Med       Date:  1981-12       Impact factor: 25.391

6.  High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis.

Authors:  J B Reed; L S Morse; I R Schwab
Journal:  Am J Ophthalmol       Date:  1998-03       Impact factor: 5.258

7.  Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease.

Authors:  D Wakefield; P McCluskey; R Penny
Journal:  Arch Ophthalmol       Date:  1986-06

8.  Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial.

Authors:  G A Chrousos; J C Kattah; R W Beck; P A Cleary
Journal:  JAMA       Date:  1993-04-28       Impact factor: 56.272

9.  Effectiveness of cyclosporin therapy for Behçet's disease.

Authors:  R B Nussenblatt; A G Palestine; C C Chan; M Mochizuki; K Yancey
Journal:  Arthritis Rheum       Date:  1985-06

10.  Acute simultaneous bilateral vestibulocochlear impairment in neuro-Behçet's disease: a case report.

Authors:  I Tsunoda; H Kanno; M Watanabe; S Shimoji; K Hirayama; H Sumita; T Yamamoto
Journal:  Auris Nasus Larynx       Date:  1994       Impact factor: 1.863

View more
  6 in total

1.  Visual aspects of Behçet's disease.

Authors:  Tulay Kansu; Sibel Kadayifcilar
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.598

2.  Behçet's disease, painful genital ulcerations and steroid pulse therapy.

Authors:  T Aldeen
Journal:  BMJ Case Rep       Date:  2009-02-27

3.  [Behcet's disease--ophthalmological and general aspects: Part 2: Therapy].

Authors:  U Pleyer; D Hazirolan; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

Review 4.  Visual aspects of Behçet's disease.

Authors:  Tulay Kansu; Sibel Kadayifcilar
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 5.  [Off-label use of infliximab].

Authors:  M Onder; C Salavastru; K Fritz
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

6.  Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.

Authors:  Fouad R Zakka; Peter Y Chang; Gian P Giuliari; C Stephen Foster
Journal:  Clin Ophthalmol       Date:  2009-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.